JPH0577641B2 - - Google Patents

Description

[Detailed description of the invention]

[Industrial Field of Application] The present invention relates to solid iodophor preparations. [Prior Art] Conventionally, as a solid iodophor preparation, there is one in which iodine is mechanically blended into a solid solution of polyvinylpyrrolidone and iodide to form a complex (for example, JP-A-50-35318). [Problems to be Solved by the Invention] However, the production of this product required complicated steps, and there was also a problem that iodine sublimated from the solid iodophor. [Means for Solving the Problems] The present inventors have conducted intensive studies to find a stable solid iodophor preparation that is easy to produce, and as a result, they have arrived at the present invention. That is, the present invention includes: iodine carrier (a), iodide
(b), an oxidizing agent (c), a powdered acid (d), and a powdered base (e) that has the property of foaming when reacted with (d);
A solid iodophor preparation (hereinafter referred to as the preparation of the present invention) characterized in that one component of (c) and (d) is molded separately from the other two components, and an iodine carrier (a),
It contains an iodide (b), an oxidizing agent (c), a powdered acid (d), and a powdered base (e) that has the property of reacting with (d) to form a foam, and contains both components (b) and (c). (d) A solid iodophor preparation characterized by separately molded components (hereinafter referred to as the preparation of the present invention), an iodine carrier (a), an iodide (b), an oxidizing agent (c), and a powdered acid. (d) and a powdered base (e) that has the property of reacting with (d) and foaming;
This is a solid iodophor preparation (hereinafter referred to as the preparation of the present invention) characterized in that (b) and (c) are separately molded. In the present invention, the iodophor preparations include those that generate iodine when dissolved in water even if they do not themselves contain iodine. In the present invention, the iodide (b) is not particularly limited as long as it is a compound that dissociates into iodine ions in an aqueous solution, and metal iodides such as alkali metal iodides (sodium iodide, potassium iodide, etc.), alkaline earth metal These include iodides (such as calcium iodide, magnesium iodide) and nonmetallic iodides (such as ammonium iodide). Among these, preferred are alkali metal iodides. As the oxidizing agent (c), iodic acid (salt) [refers to iodic acid and/or its salt]. Similar expressions will be used below. ], bromate (salt), chromic acid (salt), permanganic acid (salt), peroxyacid (salt), iodine oxide and halogenated isocyanuric acid (salt). In oxidizing agent (c), salts include alkali metal salts (sodium salts, potassium salts, etc.), alkaline earth metal salts (calcium salts, magnesium salts, etc.), and non-metal salts (ammonium salts, amine salts, etc.)
etc. can be mentioned. Among these, preferred are alkali metal salts, and particularly preferred are sodium salts and potassium salts. Examples of peroxy acids (salts) include peroxycarbonic acid (salt), peroxytitanic acid (salt), peroxyboric acid (salt), peroxysulfuric acid (salt), and peroxyphosphoric acid (salt). Iodine oxides include diiodine tetroxide, diiodine pentoxide, and tetraiodine nonaoxide. Examples of the halogenated isocyanuric acid (salt) include compounds in which 1 to 3 of the 3 hydrogens of isocyanuric acid are replaced with halogens such as chlorine, iodine, or bromine, preferably chlorine, and/or salts thereof. Among the oxidizing agents (c), iodic acids (salts) and peroxy acids (salts) are preferred from the viewpoint of appearance and stability.
and halogenated isocyanuric acid (salt),
Particularly preferred are iodates (sodium iodate, potassium iodate, etc.) and halogenated isocyanuric acids (salts) (sodium dichloroisocyanurate, trichloroisocyanurate, etc.)
It is. The formulation of the present invention may contain a powdered acid (d) and a powdered base (e) which has the property of foaming upon reaction with (d).
In the present invention, the powdered acid (d) includes a powdered acid and a powdered acid salt exhibiting acidity. Powdered acids include saturated dicarboxylic acids (oxalic acid, malonic acid, succinic acid, etc.), unsaturated dicarboxylic acids (maleic acid, fumaric acid, etc.), oxyacids (malic acid, tartaric acid, citric acid, etc.), and inorganic acids (boric acid, etc.). , pyrophosphoric acid, metaphosphoric acid, phosphorous acid, etc.). Powdered acid salts include acid salts of inorganic acids, such as hydrogen alkali metal salts of inorganic acids (sodium dihydrogen phosphate,
Examples include sodium hydrogen sulfate, etc. Among (d), preferred are oxalic acid, citric acid, and alkali metal salts of hydrogen sulfate (such as sodium salts). Powdered base (e) is a salt (normal salt, acidic salt, etc.) that exhibits the alkalinity of the powder and has the property of foaming upon reaction with (d). Examples of (e) include carbonates (alkali metal carbonates such as sodium carbonate, potassium carbonate, ammonium carbonate, etc.) and bicarbonates (alkali metal bicarbonates such as sodium bicarbonate, potassium bicarbonate, ammonium bicarbonate, etc.). can be given. (e)
Preferred among these are alkali metal hydrogen carbonate salts (sodium salts, etc.). The powdered acid, powdered acid salt, and powdered base are water-soluble, and preferably have a solubility in water of 1 g or more per 100 g of water at room temperature. The melting point or decomposition point of powdered acids, powdered acid salts and powdered bases is usually 50℃
That's all. The iodine carrier (a) may be a compound commonly used for iodophors, including surfactants and non-surfactants. Surfactants include conventional surfactants such as those described in US Pat. No. 4,331,447. Specifically, a nonionic compound having a (poly)oxyalkylene chain [(poly)oxyethylene, (poly)oxypropylene and/or (poly)oxybutylene chain] in the molecule,
Mention may be made of anionic, cationic and amphoteric surfactants. Examples of the nonionic surfactants include poly(3 to 40 mol) oxyalkylene (C ₂ to _{C 4} ) alkyl (C ₈ to C ₁₈ ) ether, polyoxyethylene alkyl (C _{8 to C 18 ) phenyl ether (polyoxyethylene alkyl (C 8} to C ₁₈ ), (oxyethylene octyl or nonylphenyl ether, etc.), polyoxyethylene/polyoxypropylene block copolymers (such as Pluronics manufactured by Wyandt Co., Ltd.), and polyoxyethylene alkyl phenyl ether formalin condensates. Examples of anionic surfactants include sulfate ester salts of the above-mentioned nonionic surfactants [polyoxyethylene alkyl (C ₈ - _{C 18} ) ether sulfate ester salts (alkali metal salts, ammonium salts and amine salts,
Hereinafter, salts in anionic activators are the same),
Polyoxyethylene alkyl (C ₈ - C ₁₂ ) phenyl ether sulfate, etc.], phosphate ester salt [Polyoxyethylene alkyl (C ₈ - _{C 18} )
ether phosphate ester salts, polyoxyethylene alkyl (C ₈ -C ₁₂ ) phenyl ether phosphate ester salts, etc.). Cationic surfactants include polyoxyalkyl ( _C2 - _C4 ) alkyl ( _C12 - _C18 ) trimethylammonium halides (iodide, etc.), and amphoteric surfactants include polyoxyalkyl (C2- _C4 ) Examples include C ₄ )-alkylaminoethylglycine. In addition, surfactants without (poly)oxyalkylene chains, such as anionic surfactants [alkyl ( _C8 - _C18 ) sulfate salts, alkyl ( _C8 - _C18 ) phosphate salts, etc.], cationic surfactants, etc. Activator [Alkyl ( _C8 - _C18 ) dimethylbenzylammonium halide, dialkyl ( _C8 - _C18 )
Dimethylammonium halide, alkyl ( _C8
~ _C20 ) trimethylammonium halide, etc.]
can also be used. These surfactants are preferably used in combination with a surfactant having a (poly)oxyalkylene chain in the molecule. Among these surfactants, preferred are nonionic surfactants having (poly)oxyalkylene chains. In addition, examples of the non-surface-active substance used as an iodine carrier include low-molecular or high-molecular weight water-soluble or water-solubilizable substances. Specifically, water-soluble sugars [glucose, fructose, lactose, sucrose,
xylitol, mannitol, sorbitol, dextrin, cyclodextrin, dextran, solubilized starch, etc.], polyvinylpyrrolidone and polyols other than sugars [low-molecular polyols such as ethylene glycol, propylene glycol, glycerin, and their alkylene oxide (ethylene oxide, etc.) adducts, e.g. polyethylene glycol, etc.]. The above-mentioned iodine carrier may be a mixture of two or more kinds. In the formulation of the present invention, the content of each component in the formulation is as follows based on the weight of the formulation. That is, the iodine carrier content is usually 0.1 to 80%, preferably 5 to 50%. The iodide content is preferably 0.01-20%, particularly preferably 0.1-10%. The amount of iodide
If it is less than 0.01%, sufficient iodine cannot be obtained to exhibit bactericidal efficacy when diluted with water. In addition, in order to generate enough iodine to exert a bactericidal effect during use, an amount of iodide of up to 20% is usually sufficient, but in the present invention, (b) and (c) are separately molded. Therefore, it is also possible to use iodide amounts of more than 20% (for example up to 70%, in particular up to 30%). Oxidizing agent usually 0.001-50%, preferably 0.1-20
%. Particularly preferably 0.1 to 10%. In the case of oxidizing agents, for the same reason as in the case of iodides,
Contents below 0.001% and above 50% are disadvantageous. Powdered acids and powdered acid salts are usually 90% or less, preferably 10-70%. If it exceeds 90%, the irritation will become stronger when using it. Powdered base (e) is usually 50% or less, preferably 5 to 40%
%. If the amount of powder base (e) exceeds 50%, the bactericidal efficacy of iodine generated during dilution with water will decrease. The weight ratio of (d) and (e) [(d)/(e)] is usually 0.1-20, preferably 1-10. If the weight ratio is less than 0.1, the bactericidal power will decrease during use, making it unsuitable. Moreover, if it exceeds 20, the dissolution rate becomes slow when the tablet preparation of the present invention is dissolved in water, which is not preferable. The preparation of the present invention may contain other compounding agents (f), such as a foaming agent, a foam suppressor, a moisture absorbent [sodium sulfate, potassium sulfate, etc.], if necessary. The preparation of the present invention comprises an iodine carrier (a), an iodide (b), an oxidizing agent (c), a powdered acid (d), and a powdered base (e) which has the property of foaming when reacted with (d) [and, if necessary, other compounding agent (f)], and one of the components (b), (c), and (d) is molded separately from the other two components; (b), ( Components other than c) and (d) may be contained in only one of the molded articles, or may be contained in both. The molding method involves mechanically blending part or all of (a), (e) [and if necessary (f)], and adding one component of (b), (c), and (d). Alternatively, two ingredients are added and formed into a powder, granule, or tablet, and the remaining ingredients are formed into powder, granules, or tablets, and each layer is formed into a layered tablet using a molding method, tableting method, extrusion method, etc. One method is to do this. These powders, granules, tablets or layered tablets may be coated with a coating agent. The shaped powders, granules or tablets may be packaged in separate bags; alternatively, a bag 3 separated by a partition 4 into two compartments 1, 2, as shown for example in FIG.
Powder, granule, or tablet containing one of the components (b), (c), and (d) in each chamber of [for example, a bag laminated with polyethylene film, etc., with partition wall 4 formed by heat sealing] () and (b), (c), (d)
A powder, granule or tablet containing the remaining two ingredients can be packaged. Also,
Granules or tablets containing one ingredient among (b), (c), and (d) are separated from granules or tablets containing the remaining two ingredients among (b), (c), and (d). It is also possible to package the product in the same bag for each use. As shown in FIGS. 2 and 3, for example, a laminated tablet may contain a layer () containing one of the components (b), (c), and (d) and a layer () containing one of the components (b), (c), ( Laminated tablets with layer (2) containing the remaining two components of d), or multilayer tablets with three or more layers, such as a layer containing one of the components (b), (c), and (d). A layer that does not contain (b), (c), or (d) is placed between and/or outside the layer () that contains the remaining two components among () and (b), (c), and (d). Examples include those having multiple layers of () and/or (). The solid iodophor preparation of the present invention dissolves rapidly when added to water. When the preparation of the present invention is dissolved in water, the effective iodine content generated is not particularly limited, but is usually 0.01 to 45%, preferably 0.1 to 45%, based on the weight of the preparation.
20%, particularly preferably 0.2-10%. The preparation of the present invention is used by diluting it with water so that the effective iodine concentration is usually several ppm to 150 ppm, but it can also be used by dissolving one part of the auxiliary agent in one part of water. [Examples] The present invention will be further described below with reference to Examples, but the present invention is not limited thereto. The raw materials used in the examples are as follows. A1: Polyethylene glycol (molecular weight 20000) A2: Polyoxyethylene nonyl phenyl ether (n: 20) A3: Polyvinylpyrrolidone (k: 20) A4: Dextran 40 B1: Sodium iodide C1: Sodium iodate, C2: Dichloroisocyanur Sodium acid D1: Oxalic acid D2: Sodium hydrogen sulfate D3: Citric acid E1: Sodium hydrogen carbonate F1: Anhydrous sodium sulfate Examples 1 to 8, Comparative examples 1 to 2 Ingredients consisting of the composition (wt%) shown in Table 1 and The components are molded separately, as shown in Figure 2.
A formulation of the invention consisting of a layered tablet as shown in FIG. 3 was prepared.

[Table] Effective iodine*1, appearance*2, and dissolution time* of the obtained preparation at the time of preparation and after 6 months at room temperature
3 was measured. The results are shown in Table 2. (Note) *1: Means iodine that can be titrated with sodium thiosulfate in the aqueous solution of the preparation. *2: ◎ indicates a white to slightly yellow tablet; × indicates a tablet with many brown spots on the tablet surface. *3: Time (minutes) required to dissolve 1 tablet (1 g) of the preparation in 100 ml of water.

[Table] [Effects of the Invention] The preparation of the present invention does not require complicated steps unlike conventional ones during production, and is simple and requires only mechanical blending. That is, conventional ones (for example, JP
35318) was manufactured using a complicated process of first preparing a polyvinylpyrrolidone-iodide solid solution by drying a solution containing polyvinylpyrrolidone and iodide, and then mechanically blending it with elemental iodine. The formulations of the invention are easy to manufacture. Furthermore, the stability of the formulation is excellent. Furthermore, when the tablet preparation is dissolved in water, it dissolves quickly and generates iodine, so it has excellent bactericidal activity. Moreover, the formulation of the present invention contains iodide (b) and an oxidizing agent.
By separately molding (c), the stability of the formulation, especially the appearance stability, is significantly improved compared to those molded at the same time, and the appearance of the formulation becomes discolored or iodine spots appear over time. It is stable for a long period of time without causing any damage, and it is also possible to increase the effective iodine concentration. Since the formulation of the present invention exhibits the above effects,
It is used in fields such as medicine, dairy farming, food processing, and environmental hygiene to disinfect the walls and floors of public buildings, disinfect and clean storage sheds and bodies, disinfect equipment for regulating equipment, and disinfect the skin of animals and humans.

[Brief explanation of drawings]

FIG. 1 is a front view of a preparation packaged in a bag separated into two compartments, and FIGS. 2 and 3 are a cross-sectional view and a perspective view, respectively, of a laminated tablet. In the figure,
is a powder or granules containing iodide or an iodide-containing layer, is a powder or granules containing an oxidizing agent or an oxidizing agent-containing layer, 1 and 2 are powders or granules containing iodide and powders or granules containing an oxidizing agent, respectively. The chamber, 3 represents the bag, and 4 represents the partition wall.

Claims (1)

[Claims] 1 Contains an iodine carrier (a), an iodide (b), an oxidizing agent (c), a powdered acid (d), and a powdered base (e) that has the property of foaming when reacted with (d). A solid iodophor preparation, characterized in that one of the components (b), (c), and (d) is molded separately from the other two components. 2 Contains an iodine carrier (a), an iodide (b), an oxidizing agent (c), a powdered acid (d), and a powdered base (e) that has the property of foaming when reacted with (d), and (b) ), a solid iodophor preparation characterized in that both components (c) and component (d) are molded separately. 3 Contains an iodine carrier (a), an iodide (b), an oxidizing agent (c), a powdered acid (d), and a powdered base (e) that has the property of foaming when reacted with (d), and (b) ) and (c) are separately molded. A solid iodophor preparation. 4. Lamination of a layer containing one or two of the components (b), (c), and (d) and a layer containing the other components (b), (c), and (d). The formulation according to any one of claims 1 to 3, which is a tablet. 5 Powders, granules or tablets containing one or two of the ingredients (b), (c) and (d) and other (b),
The formulation according to any one of claims 1 to 3, comprising a powder, granule, or tablet containing the ingredients (c) and (d). 6. Powders, granules, or tablets containing one or two of the components (b), (c), and (d) and other (b),
Powders, granules or tablets containing ingredients (c) and (d) are packaged in separate bags or separated into two
The formulation according to any one of claims 1 to 3, packaged in a bag separated into compartments.